-
公开(公告)号:US20160376244A1
公开(公告)日:2016-12-29
申请号:US15190642
申请日:2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D265/22 , C07D413/06 , C07D491/107 , C07D413/04 , C07F7/02 , C07D471/04 , C07D413/14 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
Abstract translation: 其中每个符号如所附的说明中所定义。
-
公开(公告)号:US20180303841A1
公开(公告)日:2018-10-25
申请号:US15769295
申请日:2016-10-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Takuto KOJIMA , Jinichi YONEMORI
CPC classification number: A61K31/53 , A61K31/517 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28 , C07D239/88 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/14
Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
-
3.
公开(公告)号:US20190248776A1
公开(公告)日:2019-08-15
申请号:US16394762
申请日:2019-04-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D413/14 , C07D491/107 , C07D471/04 , C07D417/06 , C07D413/10 , C07D413/06 , C07D265/22 , C07F7/02 , C07D413/04 , C07F7/08 , A61P25/28 , C07D417/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号:US20180362516A1
公开(公告)日:2018-12-20
申请号:US16113635
申请日:2018-08-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Takuto KOJIMA
IPC: C07D413/14 , C07D413/06 , C07D471/04 , C07D491/107 , C07D413/04 , C07F7/02 , C07D417/06 , C07D265/22 , C07F7/08 , C07D417/10 , A61P25/28 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号:US20180050996A1
公开(公告)日:2018-02-22
申请号:US15799379
申请日:2017-10-31
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Takuto KOJIMA
IPC: C07D265/22 , C07F7/02 , C07D491/107 , C07D471/04 , C07D417/06 , C07D413/14 , C07D413/10 , C07D413/06 , C07D413/04
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号:US20150307497A1
公开(公告)日:2015-10-29
申请号:US14443598
申请日:2013-11-18
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Shinkichi SUZUKI , Masami YAMADA , Makoto KAMATA , Takuto KOJIMA , Ikuo FUJIMORI , Kenichiro SHIMOKAWA
IPC: C07D487/04 , C07D405/14
CPC classification number: C07D487/04 , C07D209/46 , C07D401/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/14 , C07D519/00
Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.
Abstract translation: 提供具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物,可用作阿尔茨海默病,精神分裂症,疼痛,睡眠障碍等的预防或治疗药物。 本发明涉及由下式表示的化合物:其中环A是任选具有取代基的4-至7-元环; L是-O - , - S - , - SO-或-SO 2 - ; R1是任选具有取代基的C 1-6烷基(条件是当L是-O-,R 1不是被卤素原子任意取代的C 1-6烷基时)或任选具有取代基的环状基团 (s); X1为-CRa =或-N =; X2为-CRb =或-N =; X3是-CRc =或-N=; R a,R b和R c各自为任选具有取代基的C 1-6烷基,C 2-6烯基,C 1-6烷氧基,C 3-6环烷基,C 3-6环烷氧基或C 6-14芳基, H或卤素,或其盐。
-
公开(公告)号:US20210139491A1
公开(公告)日:2021-05-13
申请号:US16622632
申请日:2018-06-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Kazuaki TAKAMI , Masaki SETO , Shinobu SASAKI , Haruhi ANDO , Masaki OGINO , Tomoko OHASHI , Toshihiro IMAEDA , Ikuo FUJIMORI , Yasuhiro TSUKIMI , Masami YAMADA , Kenichiro SHIMOKAWA , Takeshi WAKABAYASHI , Masataka MURAKAMI , Makoto FUSHIMI , Tomohiro OKAWA , Jinichi YONEMORI , Tomohiro OHASHI , Hideo SUZUKI , Hironobu MAEZAKI , Ayumu SATO , Yasutomi ASANO , Steve SWANN
IPC: C07D491/048 , A61K31/4355 , A61P1/10
Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
-
8.
公开(公告)号:US20180162850A1
公开(公告)日:2018-06-14
申请号:US15735418
申请日:2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D413/14 , C07D413/10 , C07D265/22 , C07D417/10 , C07F7/08 , C07D491/107 , A61P25/28
CPC classification number: C07D265/22 , A61P25/28 , C07B2200/07 , C07D413/04 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号:US20170081332A1
公开(公告)日:2017-03-23
申请号:US15311025
申请日:2015-05-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takahiro SUGIMOTO , Kenichiro SHIMOKAWA , Takuto KOJIMA , Hiroki SAKAMOTO , Ikuo FUJIMORI , Minoru NAKAMURA , Masami YAMADA , Masataka MURAKAMI , Makoto KAMATA , Shinkichi SUZUKI
IPC: C07D487/04 , C07D471/04
CPC classification number: C07D487/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/501 , A61K31/519 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.
-
-
-
-
-
-
-
-